The drug maker Biogen reported on Wednesday that Aduhelm, its new Alzheimer’s drug, brought in $300,000 in revenue from July to September, far short of the company’s goals and Wall Street expectations.

The sales figures, which Biogen disclosed in its financial report for the third quarter, the drug’s first full period of availability, represented a remarkably slow start for a treatment that was introduced with a $56,000 annual price tag and expectations that it would strain Medicare’s…

The drug maker Biogen reported on Wednesday that Aduhelm, its new Alzheimer’s drug, brought in $300,000 in revenue from July to September, far short of the company’s goals and Wall Street expectations.

The sales figures, which Biogen disclosed in its financial report for the third quarter, the drug’s first full period of availability, represented a remarkably slow start for a treatment that was introduced with a $56,000 annual price tag and expectations that it would strain Medicare’s…

The drug maker Biogen reported on Wednesday that Aduhelm, its new Alzheimer’s drug, brought in $300,000 in revenue from July to September, far short of the company’s goals and Wall Street expectations.

The sales figures, which Biogen disclosed in its financial report for the third quarter, the drug’s first full period of availability, represented a remarkably slow start for a treatment that was introduced with a $56,000 annual price tag and expectations that it would strain Medicare’s…

The drug maker Biogen reported on Wednesday that Aduhelm, its new Alzheimer’s drug, brought in $300,000 in revenue from July to September, far short of the company’s goals and Wall Street expectations.

The sales figures, which Biogen disclosed in its financial report for the third quarter, the drug’s first full period of availability, represented a remarkably slow start for a treatment that was introduced with a $56,000 annual price tag and expectations that it would strain Medicare’s…

The drug maker Biogen reported on Wednesday that Aduhelm, its new Alzheimer’s drug, brought in $300,000 in revenue from July to September, far Extra resources short of the company’s goals and Wall Street expectations.

The sales figures, which Biogen disclosed in its financial report for the third quarter, the drug’s first full period of availability, represented a remarkably slow start for a…

The drug maker Biogen reported on Wednesday that Aduhelm, its new Alzheimer’s drug, brought in $300,000 in revenue from July to September, far short of the company’s goals and Wall Street expectations.

The sales figures, which Biogen disclosed in its financial report for the third quarter, the drug’s first full period of availability, represented a remarkably slow start for a treatment that was introduced with a $56,000 annual price tag and expectations that it would strain Medicare’s…

The drug maker Biogen reported on Wednesday that Aduhelm, its new Alzheimer’s drug, brought in $300,000 in revenue from July to September, far short of the company’s goals and Wall Street expectations.

The sales figures, which Biogen disclosed in its financial report for the third quarter, the drug’s first full period of availability, represented a remarkably slow start for a treatment that was introduced with a $56,000 annual price tag and expectations that it would strain Medicare’s…

The drug maker Biogen reported on Wednesday that Aduhelm, its new Alzheimer’s drug, brought in $300,000 in revenue from July to September, far short of the company’s goals and Wall Street expectations.

The sales figures, which Biogen disclosed in its financial report for the third quarter, the drug’s first full period of availability, represented a remarkably slow start for a treatment that was introduced with a $56,000 annual price tag and expectations that it would strain Medicare’s…

The drug maker Biogen reported on Wednesday that Aduhelm, its new Alzheimer’s drug, brought in $300,000 in revenue from July to September, far short of the company’s goals and Wall Street expectations.

The sales figures, which Biogen disclosed in its financial report for the third quarter, the drug’s first full period of availability, represented a remarkably slow start for a treatment that was introduced with a $56,000 annual price tag and expectations that it would strain Medicare’s…

The drug maker Biogen reported on Wednesday that Aduhelm, its new Alzheimer’s drug, brought in $300,000 in revenue from July to September, far short of the company’s goals and Wall Street expectations.

The sales figures, which Biogen disclosed in its financial report for the third quarter, the drug’s first full period of availability, represented a remarkably slow start for a treatment that was introduced with a $56,000 annual price tag and expectations that it would strain Medicare’s…

The drug maker Biogen reported on Wednesday that Aduhelm, its new Alzheimer’s drug, brought in $300,000 in revenue from July to September, far short of the company’s goals and Wall Street expectations.

The sales figures, which Biogen disclosed in its financial report for the third quarter, the drug’s first full period of availability, represented a remarkably slow start for a treatment that was introduced with a $56,000 annual price tag and expectations that it would strain Medicare’s…

The drug maker Biogen reported on Wednesday that Aduhelm, its new Alzheimer’s drug, brought in $300,000 in revenue from July to September, far short of the company’s goals and Wall Street expectations.

The sales figures, which Biogen disclosed in its financial report for the third quarter, the drug’s first full period of availability, represented a remarkably slow start for a treatment that was introduced with a $56,000 annual price tag and expectations that it would strain Medicare’s…

The drug maker Biogen reported on Wednesday that Aduhelm, its new Alzheimer’s drug, brought in $300,000 in revenue from July to September, far short of the company’s goals and Wall Street expectations.

The sales figures, which Biogen disclosed in its financial report for the third quarter, the drug’s first full period of availability, represented a remarkably slow start for a treatment that was introduced with a $56,000 annual price tag and expectations that it would strain Medicare’s…

The drug maker Biogen reported on Wednesday that Aduhelm, its new Alzheimer’s drug, brought in $300,000 in revenue from July to September, far short of the company’s goals and Wall Street expectations.

The sales figures, which Biogen disclosed in its financial report for the third quarter, the drug’s first full period of availability, represented a remarkably slow start for a treatment that was introduced with a $56,000 annual price tag and expectations that it would strain Medicare’s…

The drug maker Biogen reported on Wednesday that Aduhelm, its new Alzheimer’s drug, brought in $300,000 in revenue from July to September, far short of the company’s goals and Wall Street expectations.

The sales figures, which Biogen disclosed in its financial report for the third quarter, the drug’s first full period of availability, represented a remarkably slow start for a treatment that was introduced with a $56,000 annual price tag and expectations that it would strain Medicare’s…

The drug maker Biogen reported on Wednesday that Aduhelm, its new Alzheimer’s drug, brought in $300,000 in revenue from July to September, far short of the company’s goals and Wall Street expectations.

The sales figures, which Biogen disclosed in its financial report for the third quarter, the drug’s first full period of availability, represented a remarkably slow start for a treatment that was introduced with a $56,000 annual price tag and expectations that it would strain Medicare’s…

The drug maker Biogen reported on Wednesday that Aduhelm, its new Alzheimer’s drug, brought in $300,000 in revenue from July to September, far short of the company’s goals and Wall Street expectations.

The sales figures, which Biogen disclosed in its financial report for the third quarter, the drug’s first full period of availability, represented a remarkably slow start for a treatment that was introduced with a $56,000 annual price tag and expectations that it would strain Medicare’s…

The drug maker Biogen reported on Wednesday that Aduhelm, its new Alzheimer’s drug, brought in $300,000 in revenue from July to September, far short of the company’s goals and Wall Street expectations.

The sales figures, which Biogen disclosed in its financial report for the third quarter, the drug’s first full period of availability, represented a remarkably slow start for a treatment that was introduced with a $56,000 annual price tag and expectations that it would strain Medicare’s…

The drug maker Biogen reported on Wednesday that Aduhelm, its new Alzheimer’s drug, brought in $300,000 in revenue from July to September, far short of the company’s goals and Wall Street expectations.

The sales figures, which Biogen disclosed in its financial report for the third quarter, the drug’s first full period of availability, represented a remarkably slow start for a treatment that was introduced with a $56,000 annual price tag and expectations that it would strain Medicare’s…

The drug maker Biogen reported on Wednesday that Aduhelm, its new Alzheimer’s drug, brought in $300,000 in revenue from July to September, far short of the company’s goals and Wall Street expectations.

The sales figures, which Biogen disclosed in its financial report for the third quarter, the drug’s first full period of availability, represented a remarkably slow start for a treatment that was introduced with a $56,000 annual price tag and expectations that it would strain Medicare’s…